← Back to headlines
Sarepta Therapeutics Stock Surges on Positive Trial Results and Analyst Upgrade
Sarepta Therapeutics (SRPT) shares skyrocketed 35% following a price target hike from Morgan Stanley and the announcement of stellar trial results for the company.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
Study Finds Secondhand Smoke Caused Nearly 1.7 Million Deaths Globally
2h ago
Indonesia Suspends Nearly 2,000 Free Meal Kitchens Over Sanitation Violations
2h ago
Pamela Anderson Opens Up About Her 1990s Hepatitis C Diagnosis and Recovery
7h ago
Teen Girl Intubated After Electric Scooter Crash in Tinos
17h ago